Under the agreement, Twist Biopharma, a division of Twist Bioscience, will grant access to Pure Biologics to select synthetic antibody phage display libraries derived from sequences that exist only in the human body and that are optimized using artificial intelligence and big data analytics.
The companies will work together to develop new antibody candidates that are useful for immuno-oncology therapies. Certain libraries are tailored deliberately to match chosen classes of biological targets.
Pure Biologics will pay Twist technology access fees annually, as well as future payments for preclinical, clinical, and commercial achievement for any antibodies resulting from the deal.
Copyright © 2021 scienceboard.net